|
GB0013810D0
(en)
|
2000-06-06 |
2000-07-26 |
Celltech Chiroscience Ltd |
Biological products
|
|
US7122351B2
(en)
*
|
2001-10-19 |
2006-10-17 |
Zymogenetics, Inc. |
Dimerized PDGF-D and materials and methods for producing it
|
|
GB0303337D0
(en)
|
2003-02-13 |
2003-03-19 |
Celltech R&D Ltd |
Biological products
|
|
AU2004252171B2
(en)
*
|
2003-06-27 |
2011-04-21 |
Biogen Ma Inc. |
Modified binding molecules comprising connecting peptides
|
|
GB0315450D0
(en)
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
GB0315457D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
|
JP4833850B2
(ja)
|
2003-11-21 |
2011-12-07 |
ユセベ ファルマ ソシエテ アノニム |
Ｉｌ−１７活性阻害による多発性硬化症を治療するための方法
|
|
WO2005087810A2
(en)
*
|
2004-03-08 |
2005-09-22 |
Zymogenetics, Inc. |
Dimeric fusion proteins and materials and methods for producing them
|
|
AU2006203889A1
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
CRIPTO binding molecules
|
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
US8008443B2
(en)
|
2005-04-26 |
2011-08-30 |
Medimmune, Llc |
Modulation of antibody effector function by hinge domain engineering
|
|
US8129505B2
(en)
|
2005-09-14 |
2012-03-06 |
Ucb Pharma S.A. |
Comb polymers
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
MY166021A
(en)
|
2007-03-22 |
2018-05-21 |
Biogen Ma Inc |
Binding proteins,including antibodies,antibody derivatives and antibody fragments,that specifically bind cd154 and uses thereof
|
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
|
CA2700714C
(en)
|
2007-09-26 |
2018-09-11 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
|
ES2667258T3
(es)
|
2009-09-10 |
2018-05-10 |
Ucb Biopharma Sprl |
Anticuerpos multivalentes
|
|
GB0916630D0
(en)
|
2009-09-22 |
2009-11-04 |
Secr Defence |
Antibody
|
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
ES2717883T3
(es)
|
2010-03-25 |
2019-06-26 |
Ucb Biopharma Sprl |
Moléculas de DVD-LG estabilizadas con disulfuro
|
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
|
EP2565667A1
(en)
|
2011-08-31 |
2013-03-06 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Direction of arrival estimation using watermarked audio signals and microphone arrays
|
|
EP2753697A1
(en)
|
2011-09-05 |
2014-07-16 |
ETH Zürich |
Biosynthetic gene cluster for the production of peptide/protein analogues
|
|
BR112014011304B1
(pt)
|
2011-11-11 |
2022-03-03 |
UCB Biopharma SRL |
Anticorpos de ligação com albumina e fragmentos de ligação dos mesmos, proteína de fusão de anticorpo bi-específico, polinucleotídeo, célula hospedeira, processo de produção de anticorpo ou fragamento do mesmo, formulação farmacêutica e uso
|
|
US9540442B2
(en)
|
2012-08-02 |
2017-01-10 |
Jn Biosciences Llc |
Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
|
|
TW201619188A
(zh)
|
2014-03-05 |
2016-06-01 |
優稀美生物醫藥公司 |
多聚體Ｆｃ蛋白質
|
|
MA47395A
(fr)
|
2015-05-27 |
2019-12-11 |
Ucb Biopharma Sprl |
Méthode pour le traitement d'une maladie neurologique
|
|
CN108136012B
(zh)
|
2015-08-07 |
2022-10-04 |
伊麦吉纳博公司 |
靶向分子的抗原结合构建体
|
|
WO2017096361A1
(en)
|
2015-12-04 |
2017-06-08 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
AU2018382586B2
(en)
|
2017-12-14 |
2025-01-16 |
CSL Behring Lengnau AG |
Recombinant IgG Fc multimers for the treatment of neuromyelitis optica
|
|
GB201804243D0
(en)
*
|
2018-03-16 |
2018-05-02 |
Liverpool School Tropical Medicine |
Hinge sequences
|
|
CN118459594A
(zh)
|
2018-06-01 |
2024-08-09 |
诺华股份有限公司 |
针对bcma的结合分子及其用途
|
|
JP7489407B2
(ja)
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
Ｃｄ１９結合分子及びその使用
|
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
|
US20220396631A1
(en)
|
2019-05-21 |
2022-12-15 |
Lu HUANG |
Trispecific binding molecules against bcma and uses thereof
|
|
US12215148B2
(en)
|
2019-08-08 |
2025-02-04 |
Regeneron Pharmaceuticals, Inc. |
Antigen binding molecule formats
|
|
WO2021048330A1
(en)
|
2019-09-13 |
2021-03-18 |
CSL Behring Lengnau AG |
Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders
|
|
AU2020379735A1
(en)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharmaceuticals, Inc. |
N-terminal SCFV multispecific binding molecules
|
|
WO2021127495A1
(en)
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
WO2021195513A1
(en)
|
2020-03-27 |
2021-09-30 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
|
WO2021231447A1
(en)
|
2020-05-12 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Novel il10 agonists and methods of use thereof
|
|
KR20230086765A
(ko)
|
2020-10-13 |
2023-06-15 |
얀센 바이오테크 인코포레이티드 |
분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
|
|
AU2021374083A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
MX2023012974A
(es)
|
2021-05-04 |
2023-11-15 |
Regeneron Pharma |
Agonistas multiespecificos de receptores del fgf21 y sus usos.
|
|
EP4373851A2
(en)
|
2021-07-19 |
2024-05-29 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
JP2024534787A
(ja)
|
2021-08-16 |
2024-09-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
新規なｉｌ２７受容体アゴニスト及びその使用方法
|
|
JP2024544534A
(ja)
|
2021-11-11 |
2024-12-03 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｃｄ２０－ｐｄ１結合分子及びその使用方法
|
|
US20250340668A1
(en)
|
2022-05-11 |
2025-11-06 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
|
JP2025519158A
(ja)
|
2022-05-27 |
2025-06-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
インターロイキン－２プロタンパク質及びその使用
|
|
US20230391844A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
JP2025529805A
(ja)
|
2022-08-18 |
2025-09-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
インターフェロンプロタンパク質及びその使用
|
|
EP4634220A2
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|
|
WO2024138191A1
(en)
|
2022-12-23 |
2024-06-27 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
US20240247069A1
(en)
|
2023-01-13 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
EP4649088A1
(en)
|
2023-01-13 |
2025-11-19 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
US20240287186A1
(en)
|
2023-02-28 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
T cell activators and methods of use thereof
|
|
KR20250156759A
(ko)
|
2023-02-28 |
2025-11-03 |
리제너론 파아마슈티컬스, 인크. |
다가 항스파이크 단백질 결합 분자 및 이의 용도
|
|
WO2024182451A2
(en)
|
2023-02-28 |
2024-09-06 |
Regeneron Pharmaceuticals, Inc. |
Multivalent anti-spike protein binding molecules and uses thereof
|
|
US20240400687A1
(en)
|
2023-05-10 |
2024-12-05 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
WO2024238415A1
(en)
|
2023-05-12 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor antagonists and uses thereof
|
|
EP4630457A1
(en)
|
2023-08-18 |
2025-10-15 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
US20250179137A1
(en)
|
2023-12-05 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025133290A1
(en)
|
2023-12-21 |
2025-06-26 |
Temper Bio |
Protein for immune regulation
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
US20250361309A1
(en)
|
2024-05-24 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il12 receptor agonists
|
|
WO2025255480A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
WO2025259718A2
(en)
|
2024-06-11 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonists and methods of use thereof
|
